[<sup>177</sup>Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial
Listen to this summary
The PSMAddition trial aimed to evaluate the efficacy and safety of combining [^177Lu]Lu-PSMA-617 with androgen deprivation therapy (ADT) and androgen receptor pathway inhibitors (ARPI) in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer. The results indicated that this combination significantly improved radiographic progression-free survival compared to the control group, despite a higher incidence of adverse events, suggesting it may be a viable new treatment option for this patient population.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Lancet (London, England)
View all →Jul 31, 2026 · Lancet (London, England)
Multivessel coronary artery bypass grafting via small thoracotomy versus sternotomy (MIST): an investigator-initiated, international, open-label, randomised controlled trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-weekly subcutaneous zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 30, 2026 · Lancet (London, England)
Efficacy and safety of once-daily oral zenagamtide, a novel unimolecular GLP-1 and amylin receptor agonist, in adults with type 2 diabetes: a multicentre, randomised, parallel, double-blind, placebo-controlled, dose-finding, phase 2 trial
Jul 29, 2026 · Lancet (London, England)
Deramiocel heart-derived cellular therapy in advanced Duchenne muscular dystrophy (HOPE-3): a phase 3, randomised, double-blind, placebo-controlled trial
Jul 29, 2026 · Lancet (London, England)
Psoriasis
Jul 28, 2026 · Lancet (London, England)
Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study
More in Nuclear Medicine
View all →Aug 5, 2026 · The New England journal of medicine
Syncope
Jul 29, 2026 · The New England journal of medicine
Phase 2b Trial of a Na<sub>V</sub>1.8 Inhibitor for Acute Pain
Jul 22, 2026 · The New England journal of medicine
Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer
Jul 22, 2026 · The New England journal of medicine
Antiretroviral Therapy
Jul 18, 2026 · Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology
Incremental prognostic value of the hemodynamic gain index in patients undergoing exercise stress myocardial perfusion imaging
Jul 15, 2026 · The New England journal of medicine
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
